Sign up
Pharma Capital

VentriPoint Diagnostics gets gateway CE mark

Toronto-listed medtech firm VentriPoint Diagnostics Ltd (CVE:VPT) has announced a major step forward for its breakthrough whole heart analysis system - a European CE mark. Dr.George Adams, CEO, tells Proactive how this is a 'gateway' moment to other markets worldwide with hypertension becoming a critical health epidemic and the leading cause of death among Western nations.. The group's VMSplus device can now be sold to aid in-heart treatment throughout the European Union. Shares surged almost 22% in Toronto to C$0.39. As the definition of hypertension has also recently been changed, governments and health providers across the world are now keen to identify the risk early and treat the condition, rather than let it go undiagnosed which often leads to expensive surgery.

 

View full VPT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.